The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

2.

Research identifies nearly 200 potential breast carcinogens in food packaging materials

3.

Study Hints at Survival Benefit With Transplant for Metastatic Lung Cancer

4.

AI is useful in low-resource areas for triaging breast masses.

5.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot